Global Oncology Pharmaceuticals Market
商品番号 : SMB-67519
| 出版社 | BCC Research |
| 出版年月 | 2024年10月 |
| ページ数 | 181 |
| 価格タイプ | シングルユーザライセンス |
| 価格 | USD 5,500 |
| 種別 | 英文調査報告書 |
Report Highlights
The global market for oncology pharmaceuticals is estimated to increase from $196.4 billion in 2023 to reach $401.4 billion by 2029, at a compound annual growth rate (CAGR) of 12.7% from 2024 through 2029.
腫瘍用薬剤の世界市場は、2023年の1,964億ドルから増加し、2024年から2029年までの年間平均成長率（CAGR）は12.7%で、2029年までに4,014億ドルに達すると推定されています。
Summary:
The global market for oncology pharmaceuticals was valued at $196.4 billion in 2023. The market is expected to grow at a compound annual growth rate (CAGR) of 12.7% to reach $401.4 billion by the end of 2029. Several factors make the oncology pharmaceutical industry a prime candidate for growth. The oncology pharmaceuticals market is a dynamic and quickly changing sector within the global pharmaceuticals industry. The main priorities of this market are the development, manufacture, and marketing of medications used to treat cancer. It is anticipated to keep expanding due to continuous scientific and technological breakthroughs. Novel immunotherapies and CAR-T cell therapy are emerging treatments that can completely transform how cancer is treated. However, to ensure that new therapies help a wide range of patients, it will be imperative to address issues about drug affordability and accessibility.
The pharmaceutical industry’s pipeline and portfolio in oncology is among the most diverse due to its strong emphasis on research. Over time, improved methods of screening, diagnosis, surgery, and radiation therapy, along with rapidly growing options for systemic treatment, have improved the prognosis for many cancers.
Global funding for cancer research has increased dramatically over the past 20 years, and the rate at which new drugs are being developed has not slowed. The FDA approved 161 new cancer therapeutics between 2017 and 2022 for various solid tumor malignancies and indications. The arsenal of cancer treatments is growing at a very rapid pace, which has led to a significant increase in treatment and regulatory complexity. Cancer treatment is now far more expensive for patients and healthcare systems due to the high cost of many new medications. These difficulties and expenses go beyond solid adult cancers to the pediatric and hematology/oncology fields.
Targeted therapy holds a significant market share regarding medication class, and new precision medicine techniques are emerging from an improved molecular understanding of cancer. As the incidence of breast cancer rises worldwide, pharmaceutical companies are focusing more and more on early diagnosis and treatment options.
Report Scope
This report seeks to deliver an in-depth analysis of the worldwide oncology pharmaceuticals (cancer medications) market. It includes a thorough overview of various types of oncology drugs, such as targeted therapy, immunotherapy, chemotherapy, and hormone therapy, and an examination of current and historical market revenues. The oncology pharmaceuticals market is further categorized by indication, including lung cancer, multiple myeloma, breast cancer, non-Hodgkin’s lymphoma, prostate cancer, colorectal cancer, and other types of cancer. Additionally, the report presents the market revenue for each geographic region, including North America, Europe, Asia-Pacific, and the Rest of the World (RoW).
In order to provide an in-depth understanding of the market, this report also includes profiles of market participants, the competitive landscape, key competitors, and respective market share/ranking. This report includes an oncology pharmaceuticals pipeline analysis, patent analysis, and a detailed discussion of key marketed products. This report outlines the driving and restraining factors of the oncology pharmaceuticals market.
By geography, the market in this report is segmented into four regions: North America, Europe, Asia-Pacific, and Rest of the World (RoW). For market estimates, data has been provided for 2023 as the base year, with forecasts for 2024 through 2029.
Report Synopsis
| Report Metrics | Details | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Base year considered | 2023 | ||||||||||||
| Forecast period considered | 2024-2029 | ||||||||||||
| Base year market size | $196.4 billion | ||||||||||||
| Market size forecast | $401.4 billion | ||||||||||||
| Growth rate | CAGR of 12.7% for the forecast period of 2024-2029 | ||||||||||||
| Units considered | $ Millions | ||||||||||||
| Segments covered | Drug Type, Cancer Type, Region | ||||||||||||
| Regions covered | North America, Europe, Asia-Pacific, Rest of the World | ||||||||||||
| Key Market Drivers |
| ||||||||||||
| Companies studied |
|
Report Includes
– 70 data tables and 50 additional tables
– Analysis of the global market for oncology pharmaceuticals (cancer drugs)
– Analyses of global market trends, with market revenue data from 2022 to 2023, estimates for 2024, forecast for 2025, and projected CAGRs through 2029
– An assessment of the different oncology pharmaceutical types (targeted therapy, immunotherapy, chemotherapy and hormone therapy) and their current and historical market revenues
– Estimate of the current market size and revenue prospects, along with a market share analysis by drug type, disease indication (application type), and region
– Facts and figures pertaining to the market dynamics, technological advances, regulations, and the macroeconomic factors that influence the industry
– A Porter’s Five Forces model, and global supply chain and PESTLE analyses
– An analysis of the key products on the market and promising new pipeline molecules or drugs under development
– A look at the recent patent grants
– Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, ESG score analysis, and the ESG practices of leading companies
– Analysis of the industry structure, including companies’ market shares, strategic alliances, M&A activity and a venture funding outlook
– Company profiles of major players within the industry, including Bristol-Myers Squibb Co., Merck & Co. Inc., F. Hoffmann-La Roche Ltd., Johnson & Johnson Services Inc., and AstraZeneca.
Table of Contents
Chapter 1 Executive Summary
Market Outlook
Scope of Report
Market Summary
Chapter 2 Market Overview
Overview
Supply Chain Analysis
Research and Development
Manufacturing
Packaging
Wholesale Distributors and Repackagers
Pharmacies
Dispensed to Consumers
Addressing Challenges in the Pharmaceutical Supply Chain
Costs
Regulations
Safety and Security
Porter’s Five Forces Analysis in the Oncology Market
Threat of New Entrants
Bargaining Power of Suppliers
Bargaining Power of Buyers
Threat of Substitute Products or Services
Industry Rivalry
Chapter 3 Market Dynamics
Market Dynamics
Market Drivers
Increasing Incidence of Cancer Disease
Robust Approval of Oncology Drugs
Technological Advances in Cancer Treatments
Market Challenges
Loss of Exclusivity and Genericization
Lack of Oncology Professionals
Chapter 4 Emerging Trends and Pipeline Analysis
Emerging Technologies
Personalized Cancer Vaccines
CAR T-Cell Therapy
Tablet to Cut Breast Cancer Risk
Nanoparticles
Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC)
New Developments
Biosimilar Approvals
Pipeline Analysis
Clinical Trial Analysis
Patent Analysis
Chapter 5 Market Segmentation Analysis
Segmentation Breakdown
Global Oncology Pharmaceuticals Market by Drug Type
Immunotherapy
Targeted Therapy
Chemotherapy
Hormone Therapy
Global Oncology Pharmaceuticals Market by Cancer Type
Lung Cancer
Breast Cancer
Leukemia
Melanoma
Multiple Myeloma
Prostate Cancer
Non-Hodgkin’s Lymphoma
Colorectal Cancer
Other Cancers
Geographic Breakdown
Global Oncology Pharmaceuticals Market by Region
North America
Europe
Asia-Pacific
Rest of World
Chapter 6 Competitive Intelligence
Overview
Blockbuster Oncology Pharmaceutical Brands
Global Market Shares of Leading Companies
Chapter 7 Sustainability in the Oncology Pharmaceuticals Market: ESG Perspective
Role of ESG in the Pharma Industry
Environmental
Social
Governance
ESG Risk Ratings
Conclusion
Chapter 8 Appendix
Methodology
Sources
Acronyms
Company Profiles
ABBVIE INC.
AMGEN INC.
ASTRAZENECA
BRISTOL-MYERS SQUIBB CO.
- HOFFMANN-LA ROCHE LTD.
JOHNSON & JOHNSON SERVICES INC.
LILLY
MERCK & CO. INC.
NOVARTIS AG
PFIZER INC.
SANOFI
TAKEDA PHARMACEUTICAL CO. LTD.
List of Tables
Summary Table : Global Oncology Pharmaceuticals Market, by Drug Type, Through 2029
Table 1 : Number of Oncology Drug Approvals, 2020-2024*
Table 2 : Novel Oncology Drug Approvals, 2021-2024*
Table 3 : FDA Approved Biosimilar for Oncology Indications, 2015-2024
Table 4 : Overview of Biosimilars and Interchangeable Biosimilars Approved, by FDA
Table 5 : EMA Approved Biosimilar for Oncology Indications, 2007-2024
Table 6 : List of Selected Clinical Trials Studies on Oncology Drugs Started in 2021
Table 7 : List of Selected Clinical Trials Studies on Oncology Drugs Started in 2022
Table 8 : List of Selected Clinical Trials Studies on Oncology Drugs Started in 2023
Table 9 : List of Selected Clinical Trials Studies on Oncology Drugs Started in 2024
Table 10 : Top IPCR Classification Codes and Their Descriptions
Table 11 : Global Oncology Pharmaceuticals Market, by Drug Type, Through 2029
Table 12 : Global Oncology Pharmaceuticals Market for Immunotherapy Drugs, by Region, Through 2029
Table 13 : Global Oncology Pharmaceuticals Market for Immunotherapy Drugs, by Type, Through 2029
Table 14 : FDA-Approved Immune Checkpoint Inhibitor Drugs and Their Disease Indications
Table 15 : Global Oncology Pharmaceuticals Market for Targeted Therapy Drugs, by Type, Through 2029
Table 16 : Global Oncology Pharmaceuticals Market for Targeted Therapy Drugs, by Region, Through 2029
Table 17 : Global Oncology Pharmaceuticals Market for Chemotherapy Drugs, by Region, Through 2029
Table 18 : Global Oncology Pharmaceuticals Market for Hormone Therapy Drugs, by Region, Through 2029
Table 19 : Global Oncology Pharmaceuticals Market, by Cancer Type, Through 2029
Table 20 : Global Oncology Pharmaceuticals Market for Lung Cancer, by Region, Through 2029
Table 21 : Global Oncology Pharmaceuticals Market for Breast Cancer, by Region, Through 2029
Table 22 : Global Oncology Pharmaceuticals Market for Leukemia, by Region, Through 2029
Table 23 : Global Oncology Pharmaceuticals Market for Melanoma, by Region, Through 2029
Table 24 : Global Oncology Pharmaceuticals Market for Multiple Myeloma, by Region, Through 2029
Table 25 : Global Oncology Pharmaceuticals Market for Prostate Cancer, by Region, Through 2029
Table 26 : Global Oncology Pharmaceuticals Market for Non-Hodgkin’s Lymphoma, by Region, Through 2029
Table 27 : Global Oncology Pharmaceuticals Market for Colorectal Cancer, by Region, Through 2029
Table 28 : Global Oncology Pharmaceuticals Market for Other Type of Cancers, by Region, Through 2029
Table 29 : Global Oncology Pharmaceuticals Market, by Region, Through 2029
Table 30 : North American Oncology Pharmaceuticals Market, by Drug Type, Through 2029
Table 31 : North American Oncology Pharmaceuticals Market, by Cancer Type, Through 2029
Table 32 : North American Market for Oncology Pharmaceuticals, by Country, Through 2029
Table 33 : U.S. Oncology Pharmaceuticals Market, by Drug Type, Through 2029
Table 34 : U.S. Oncology Pharmaceuticals Market, by Cancer Type, Through 2029
Table 35 : Canadian Oncology Pharmaceuticals Market, by Drug Type, Through 2029
Table 36 : Canadian Oncology Pharmaceuticals Market, by Cancer Type, Through 2029
Table 37 : Mexican Oncology Pharmaceuticals Market, by Drug Type, Through 2029
Table 38 : Mexican Oncology Pharmaceuticals Market, by Cancer Type, Through 2029
Table 39 : European Oncology Pharmaceuticals Market, by Drug Type, Through 2029
Table 40 : European Oncology Pharmaceuticals Market, by Cancer Type, Through 2029
Table 41 : European Market for Oncology Pharmaceuticals Market, by Country, Through 2029
Table 42 : German Oncology Pharmaceuticals Market, by Drug Type, Through 2029
Table 43 : German Oncology Pharmaceuticals Market, by Cancer Type, Through 2029
Table 44 : U.K. Oncology Pharmaceuticals Market, by Drug Type, Through 2029
Table 45 : U.K. Oncology Pharmaceuticals Market, by Cancer Type, Through 2029
Table 46 : French Oncology Pharmaceuticals Market, by Drug Type, Through 2029
Table 47 : French Oncology Pharmaceuticals Market, by Cancer Type, Through 2029
Table 48 : Spanish Oncology Pharmaceuticals Market, by Drug Type, Through 2029
Table 49 : Spanish Oncology Pharmaceuticals Market, by Cancer Type, Through 2029
Table 50 : Italian Oncology Pharmaceuticals Market, by Drug Type, Through 2029
Table 51 : Italian Oncology Pharmaceuticals Market, by Cancer Type, Through 2029
Table 52 : Rest of the European Oncology Pharmaceuticals Market, by Drug Type, Through 2029
Table 53 : Rest of the European Oncology Pharmaceuticals Market, by Cancer Type, Through 2029
Table 54 : Asia-Pacific Oncology Pharmaceuticals Market, by Drug Type, Through 2029
Table 55 : Asia-Pacific Oncology Pharmaceuticals Market, by Cancer Type, Through 2029
Table 56 : Asia-Pacific Market for Oncology Pharmaceuticals, by Country, Through 2029
Table 57 : Chinese Oncology Pharmaceuticals Market, by Drug Type, Through 2029
Table 58 : Chinese Oncology Pharmaceuticals Market by Cancer Type, Through 2029
Table 59 : Japanese Oncology Pharmaceuticals Market, by Drug Type, Through 2029
Table 60 : Japanese Oncology Pharmaceuticals Market, by Cancer Type, Through 2029
Table 61 : Indian Oncology Pharmaceuticals Market, by Drug Type, Through 2029
Table 62 : Indian Oncology Pharmaceuticals Market, by Cancer Type, Through 2029
Table 63 : South Korean Oncology Pharmaceuticals Market, by Drug Type, Through 2029
Table 64 : South Korean Oncology Pharmaceuticals Market by Cancer Type, Through 2029
Table 65 : Rest of Asia-Pacific Oncology Pharmaceuticals Market, by Drug Type, Through 2029
Table 66 : Rest of Asia-Pacific Oncology Pharmaceuticals Market, by Cancer Type, Through 2029
Table 67 : Rest of World Oncology Pharmaceuticals Market, by Drug Type, Through 2029
Table 68 : Rest of World Oncology Pharmaceuticals Market, by Cancer Type, Through 2029
Table 69 : ESG Risk Rankings for Oncology Pharmaceuticals Companies, 2023*
Table 70 : Report Information Sources
Table 71 : Glossary of Terms Used in the Global Oncology Pharmaceuticals Market
Table 72 : AbbVie Inc.: Company Snapshot
Table 73 : AbbVie Inc.: Financial Performance, FY 2022 and 2023
Table 74 : AbbVie Inc.: Product Portfolio
Table 75 : AbbVie Inc.: News/Key Developments, 2023 and 2024
Table 76 : Amgen Inc.: Company Snapshot
Table 77 : Amgen Inc.: Financial Performance, FY 2022 and 2023
Table 78 : Amgen Inc.: Product Portfolio
Table 79 : Amgen Inc.: News/Key Developments, 2022–2024
Table 80 : AstraZeneca: Company Snapshot
Table 81 : AstraZeneca: Financial Performance, FY 2022 and 2023
Table 82 : AstraZeneca: Product Portfolio
Table 83 : AstraZeneca: News/Recent Developments, 2022−2024
Table 84 : Bristol-Myers Squibb Co.: Company Snapshot
Table 85 : Bristol-Myers Squibb Co.: Financial Performance, FY 2022 and 2023
Table 86 : Bristol-Myers Squibb Co.: Product Portfolio
Table 87 : Bristol-Myers Squibb Co.: News/Key Developments, 2023 and 2024
Table 88 : F. Hoffmann-La Roche Ltd.: Company Snapshot
Table 89 : F. Hoffmann-La Roche Ltd.: Financial Performance, FY 2022 and 2023
Table 90 : F. Hoffmann-La Roche Ltd.: Product Portfolio
Table 91 : F. Hoffmann-La Roche Ltd.: News/Key Developments, 2022–2024
Table 92 : Johnson & Johnson Services Inc.: Company Snapshot
Table 93 : Johnson & Johnson Services Inc.: Financial Performance, FY 2022 and 2023
Table 94 : Johnson & Johnson Services Inc.: Product Portfolio
Table 95 : Johnson & Johnson Services Inc.: News/Key Developments, 2022−2024
Table 96 : Lilly: Company Snapshot
Table 97 : Lilly: Financial Performance, FY 2022 and 2023
Table 98 : Lilly: Product Portfolio
Table 99 : Lilly: News/Key Developments, 2023 and 2024
Table 100 : Merck & Co. Inc.: Company Snapshot
Table 101 : Merck & Co. Inc.: Financial Performance, FY 2022 and 2023
Table 102 : Merck & Co. Inc.: Product Portfolio
Table 103 : Merck & Co. Inc.: News/Key Developments, 2021–2024
Table 104 : Novartis AG: Company Snapshot
Table 105 : Novartis AG: Financial Performance, FY 2022 and 2023
Table 106 : Novartis AG: Product Portfolio
Table 107 : Novartis AG: News/Key Developments, 2022–2024
Table 108 : Pfizer Inc.: Company Snapshot
Table 109 : Pfizer Inc.: Financial Performance, FY 2022 and 2023
Table 110 : Pfizer Inc.: Product Portfolio
Table 111 : Pfizer Inc.: News/Key Developments, 2021–2024
Table 112 : Sanofi: Company Snapshot
Table 113 : Sanofi: Financial Performance, FY 2022 and 2023
Table 114 : Sanofi: Product Portfolio
Table 115 : Sanofi: News/Key Developments, 2022–2024
Table 116 : Takeda Pharmaceutical Co. Ltd.: Company Snapshot
Table 117 : Takeda Pharmaceutical Co. Ltd.: Financial Performance, FY 2022 and 2023
Table 118 : Takeda Pharmaceutical Co. Ltd.: Product Portfolio
Table 119 : Takeda Pharmaceutical Co. Ltd.: News/Key Developments, 2021–2024
List of Figures
Summary Figure : Global Oncology Pharmaceuticals Market, by Drug Type, 2021–2029
Figure 1 : Supply Chain Process of Pharmaceutical Drugs
Figure 2 : Market Dynamics of Global Oncology Pharmaceuticals Market
Figure 3 : Cancer Incidence in the U.S., 2000–2021
Figure 4 : Share of Incidence Cases of All Cancer Types, Both Sexes, by WHO Region, 2022
Figure 5 : Novel Oncology Drugs with FDA Approvals, 2016-2024
Figure 6 : Clinical Trial Studies of Oncology Drugs, by Trial Phase, 2021-2024*
Figure 7 : Clinical Trial Studies of Oncology Drugs, by Company, 2021-2024
Figure 8 : Top IPCR Classification Codes, 2020-2024
Figure 9 : Global Oncology Pharmaceuticals Market Share, by Drug Type, 2023
Figure 10 : Global Oncology Pharmaceuticals Market Share for Immunotherapy Drugs, by Region, 2023
Figure 11 : Global Oncology Pharmaceuticals Market Share for Targeted Therapy, by Region, 2023
Figure 12 : Timeline for U.S. FDA‐Approved Small Molecule Inhibitors Targeting Cancers
Figure 13 : Global Oncology Pharmaceuticals Market Share for Chemotherapy Drugs, by Region, 2023
Figure 14 : Global Oncology Pharmaceuticals Market Share for Hormone Therapy Drugs, by Region, 2023
Figure 15 : Global Oncology Pharmaceuticals Market Share, by Cancer Type, 2023
Figure 16 : Share of Global Cancer Incidence Cases in Both Sexes, by Cancer Type, 2022
Figure 17 : Share of Global Cancer Mortality Cases in Both Sexes, by Cancer Type, 2022
Figure 18 : Global Lung Cancer Incidence and Mortality Numbers in Both Sexes, by WHO Region, 2022
Figure 19 : Global Oncology Pharmaceuticals Market Share for Lung Cancer, by Region, 2023
Figure 20 : Global Breast Cancer Incidence and Mortality Numbers in Both Sexes, by WHO Region, 2022
Figure 21 : Global Oncology Pharmaceuticals Market Share for Breast Cancer, by Region, 2023
Figure 22 : Global Leukemia Incidence and Mortality Numbers in Both Sexes, by WHO Region, 2022
Figure 23 : Global Oncology Pharmaceuticals Market Share for Leukemia, by Region, 2023
Figure 24 : Global Melanoma Incidence and Mortality Numbers in Both Sexes, by WHO Region, 2022
Figure 25 : Global Oncology Pharmaceuticals Market Share for Melanoma, by Region, 2023
Figure 26 : Global Multiple Myeloma Cancer Incidence and Mortality Numbers in Both Sexes, by WHO Region, 2022
Figure 27 : Global Oncology Pharmaceuticals Market Share for Multiple Myeloma, by Region, 2023
Figure 28 : Global Prostate Cancer Incidence and Mortality Numbers in Both Sexes, by WHO Region, 2022
Figure 29 : Global Oncology Pharmaceuticals Market Share for Prostate Cancer, by Region, 2023
Figure 30 : Global Non-Hodgkin’s Lymphoma Cancer Incidence and Mortality Numbers in Both Sexes, by WHO Region, 2022
Figure 31 : Global Oncology Pharmaceuticals Market Share for Non-Hodgkin’s Lymphoma, by Region, 2023
Figure 32 : Global Colon Cancer Incidence and Mortality Numbers in Both Sexes, by WHO Region, 2022
Figure 33 : Global Oncology Pharmaceuticals Market Share for Colorectal Cancer, by Region, 2023
Figure 34 : Global Oncology Pharmaceuticals Market Share for Other Type of Cancers, by Region, 2023
Figure 35 : Global Oncology Pharmaceuticals Market Share, by Region, 2023
Figure 36 : North American Market Share of Oncology Pharmaceuticals, by Country, 2023
Figure 37 : European Market Share of Oncology Pharmaceuticals, by Country, 2023
Figure 38 : Asia-Pacific Market Share of Oncology Pharmaceuticals, by Country, 2023
Figure 39 : Top 10 Blockbuster Oncology Pharmaceutical Drugs, by Sales Revenue, 2023
Figure 40 : Company Share Analysis of Oncology Pharmaceutical Manufacturers, 2023
Figure 41 : AbbVie Inc.: Revenue Share, by Business Unit, FY 2023
Figure 42 : AbbVie Inc.: Revenue Share, by Country/Region, FY 2023
Figure 43 : Amgen Inc.: Revenue Share, by Business Unit, FY 2023
Figure 44 : Amgen Inc.: Revenue Share, by Country/Region, FY 2023
Figure 45 : AstraZeneca: Revenue Share, by Business Unit, FY 2023
Figure 46 : AstraZeneca: Revenue Share, by Region/Country, FY 2023
Figure 47 : Bristol-Myers Squibb Co.: Revenue Share, by Business Unit, FY 2023
Figure 48 : Bristol-Myers Squibb Co.: Revenue Share, by Country/Region, FY 2023
Figure 49 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Business Unit, FY 2023
Figure 50 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Country/Region, FY 2023
Figure 51 : Johnson & Johnson Services Inc.: Revenue Share, by Business Unit, FY 2023
Figure 52 : Johnson & Johnson Services Inc.: Revenue Share, by Country/Region, FY 2023
Figure 53 : Lilly: Revenue Share, by Business Unit, FY 2023
Figure 54 : Lilly: Revenue Share, by Country/Region, FY 2023
Figure 55 : Merck & Co. Inc.: Revenue Share, by Business Unit, FY 2023
Figure 56 : Merck & Co. Inc.: Revenue Share, by Country/Region, FY 2023
Figure 57 : Novartis AG: Revenue Share, by Business Unit, FY 2023
Figure 58 : Novartis AG: Revenue Share, by Country/Region, FY 2023
Figure 59 : Pfizer Inc.: Revenue Share, by Business Unit, FY 2023
Figure 60 : Pfizer Inc.: Revenue Share, by Country/Region, FY 2023
Figure 61 : Sanofi: Revenue Share, by Business Unit, FY 2023
Figure 62 : Sanofi: Revenue Share, by Country/Region, FY 2023
Figure 63 : Takeda Pharmaceutical Co. Ltd.: Revenue Share, by Business Unit, FY 2023
Figure 64 : Takeda Pharmaceutical Co. Ltd.: Revenue Share, by Region, FY 2023
BCC Research（BCCリサーチ）はライフサイエンス、センサ、マテリアル、環境、商取引関連市場を中心とした広範な市場調査レポートを出版する米国の調査会社です。
ライセンス別価格表
2024年11月より価格構成が大幅に変更になりました。最新の価格についてはお問合せください。
調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。
新価格表
ライセンスタイプ1
| シングルユーザ | 2-5ユーザ | サイト | エンタープライズ |
| USD 4,650 | USD 5,580 | USD 6,696 | USD 8,035 |
ライセンスタイプ2
| シングルユーザ | 2-5ユーザ | サイト | エンタープライズ |
| USD 2,950 | USD 3,540 | USD 4,248 | USD 5,098 |
ライセンスタイプ3
| シングルユーザ | 2-5ユーザ | サイト | エンタープライズ |
| USD 2,500 | USD 3,000 | USD 3,600 | USD 4,320 |
旧価格表
旧ライセンスタイプ1
| シングルユーザ | 2-5ユーザ | サイト | エンタープライズ |
| USD 5,500 | USD 6,600 | USD7.920 | USD 9,504 |
旧ライセンスタイプ2
| シングルユーザ | 2-5ユーザ | サイト | エンタープライズ |
| USD 3,500 | USD 4,200 | USD 5,040 | USD 6,048 |
ご購入に関するご案内
価格・納期について
- 価格
- ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
- ライセンス
- シングルユーザライセンス
- 1名のみレポートファイルのご利用が可能です。
- 2-5ライセンス
- 同一企業内5名までレポートファイルのご利用が可能です。
- サイトライセンス
- 同一企業同住所内でレポートファイルのご利用が可能です。
- エンタープライズライセンス
- 同一企業内人数無制限でレポートファイルのご利用が可能です。
- シングルユーザライセンス
- 納品形態
- Eメール
- 納期
- ご注文後3営業日以内
ご注文方法
- レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。
その他
- 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。
BCC Researchが出版する調査レポートのサンプルページのご依頼、見積り、ご質問など購入前のご相談はいつでもお気軽にご連絡ください。
最新調査レポート
- 食品小売業およびEコマースにおけるAIの世界市場 2025-11-14
- 免疫療法薬の世界市場 2025-11-12
- 農業におけるAIの世界市場 2025-11-10
- 固体酸化物形燃料電池の技術と世界市場 2025-11-07
- 世界の電気アーク炉市場 2025-11-07
